Report Highlights

Surgical Stents in the U.S.: Market Overview

The U.S. surgical stents market, spanning coronary, peripheral vascular, biliary, and urological devices, was valued at USD 4.12 billion in 2024 and is forecast to reach USD 6.41 billion by 2032 at a 5.7% CAGR. Coronary drug-eluting stents form the largest revenue pool, supported by Medicare coverage of percutaneous coronary intervention. The structure is consolidated: Boston Scientific, Abbott Vascular, Medtronic, and Becton Dickinson hold most coronary and peripheral volume, while Cook Medical, W. L. Gore & Associates, and Merit Medical compete in endovascular and non-vascular niches.

Government has been the dominant force in demand formation, not in manufacturing. The Centers for Medicare and Medicaid Services (CMS) sets stent reimbursement through the Inpatient Prospective Payment System's MS-DRG 246 to 251 bundles and the Hospital Outpatient Prospective Payment System, which together determine where and how often stents are implanted. Private manufacturers have led device innovation, with the FDA's Premarket Approval pathway under Section 515 of the Federal Food, Drug, and Cosmetic Act governing entry for Class III coronary products, while integrated delivery networks shape purchasing through group contracts.

Policy-Driven Growth in U.S. Surgical Stents

Three mechanisms drive demand most directly. First, the New Technology Add-On Payment (NTAP) under the annual IPPS final rule reimburses hospitals 65% of the cost of qualifying new stent technologies above the standard MS-DRG payment, so hospitals adopt newly approved stents faster than DRG rates alone would allow. Second, CMS finalised the Transitional Coverage for Emerging Technologies (TCET) pathway in August 2024, which caps participation at five breakthrough devices per year and extends Medicare coverage under coverage with evidence development while clinical data accumulates.

Third, Section 515B of the Federal Food, Drug, and Cosmetic Act, created by the 21st Century Cures Act of 2016, establishes the Breakthrough Devices Program, which grants FDA priority interactive review for devices treating life-threatening or irreversibly debilitating conditions. Designees accelerate their path to Medicare coverage through TCET. Together, these mechanisms convert regulatory authorisation into reimbursed procedure volume, which is the direct driver of the market's 5.7% CAGR.

Regulatory Barriers and Compliance Costs

The FDA's Center for Devices and Radiological Health (CDRH) administers the PMA process for Class III coronary stents. Standard original PMA user fees exceeded USD 575,000 in FY2025 under the Medical Device User Fee Amendments (MDUFA V), and the 180-day FDA review goal rarely equals total elapsed time once manufacturers answer major deficiency letters. Manufacturers also face Certificate of Need requirements administered by state health departments; New York's Public Health Law Article 28 requires approval before a hospital adds cardiac catheterisation services, delaying new stent-using capacity by months.

Sterilisation adds a second layer. Most vascular stents are sterilised with ethylene oxide (EtO), which the Environmental Protection Agency regulates under the Commercial Sterilizer National Emission Standards for Hazardous Air Pollutants at 40 CFR Part 63 Subpart O, tightened in 2024 to lower permitted emissions and increase monitoring. Supply exposure rises further because the Department of Commerce's Section 232 investigation into imported medical devices, opened in 2025, threatens to raise landed costs for imported nitinol components.

Policy-Created Opportunities in the U.S.

The TCET pathway and the Breakthrough Devices Program create a near-term opportunity for manufacturers of bioresorbable and drug-coated peripheral stents that lack established Medicare coverage. Designees completing TCET participation gain coverage while funding the post-market registries CMS requires, converting clinical evidence into national coverage. Veterans Affairs procurement offers a second channel: the VA National Acquisition Center manages medical device Federal Supply Schedule contracts under FAR Subpart 8.4, awarding multi-year price agreements to compliant suppliers.

A third opportunity arises from the QMSR, effective February 2, 2026, which requires manufacturers to align quality systems with ISO 13485:2016. Contract manufacturers certifying early can capture supply agreements from stent makers seeking audit-ready partners. Domestic manufacturing gains follow directly from the Section 232 outcome, as tariffs raise the landed cost of imported finished stents relative to devices assembled with domestically sourced nitinol.

Market at a Glance

Leading Market Participants

• Boston Scientific
• Abbott Vascular
• Medtronic
• Becton Dickinson
• Cook Medical
• Terumo
• Biotronik
• W. L. Gore & Associates
• Cordis
• Merit Medical

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act (FD&C Act), administered by FDA's CDRH. Section 510(k) and Section 515 set premarket pathways, Section 515B governs breakthrough designation, and 21 CFR Part 820 sets quality system requirements. Compliance obligations include Medical Device Reporting under 21 CFR Part 803, requiring reports within 30 calendar days of a death or serious injury, and Unique Device Identification under 21 CFR Part 830. Physician payment disclosure falls under Open Payments, codified at Section 6002 of the Affordable Care Act and implemented at 42 CFR Part 403 Subpart I.

The QMSR amending 21 CFR Part 820 takes effect February 2, 2026, incorporating ISO 13485:2016 by reference. MDUFA VI negotiations covering FY2028 to FY2032 must conclude with congressional reauthorisation by September 30, 2027. Against regional peers, U.S. PMA reviews typically run 12 to 18 months, broadly comparable to EU MDR notified body reviews, which Regulation (EU) 2023/607 supports through an extended legacy transition for Class III implantables to December 31, 2027. Japan's PMDA requires local clinical data, placing the U.S. framework between the two.

Long-Term Policy Outlook for U.S. Surgical Stents

MDUFA VI reauthorisation by September 30, 2027 will set FDA review performance goals through FY2032 and determine whether PMA review capacity keeps pace with breakthrough designations. CMS will revise MS-DRG relative weights in each annual IPPS rule through 2032, directly altering hospital margins on PCI with stent implantation. TCET participation caps will shape how quickly new peripheral and bioresorbable devices reach reimbursed use.

Section 232 tariff outcomes will reshape supply chains by 2032, pushing domestic nitinol processing and EtO-alternative sterilisation higher on manufacturer investment agendas. The QMSR transition will consolidate suppliers that cannot meet audit standards. By 2032, the market's USD 6.41 billion value will rest on procedure volume from the aging population rather than on price.